M-2000, as a new anti-inflammatory molecule in treatment of experimental nephrosis
MetadataShow full item record
The therapeutic effect of M‐2000 (C6H10O7) molecule was tested in Adriamycin‐induced nephropathy. To induce experimental nephrosis, Adriamycin was given once by a single intravenous injection (7.5 mg/kg) through the tail vein. Six days after injection of Adriamycin, therapeutic protocol was developed by intraperitoneally (i.p) administration of 30 mg/kg M‐2000 solution. Total of i.p. injections were 14, in which five injections were made every day and nine injections were carried out at regular 48‐h intervals. Therapeutic protocol was terminated on day 28 and animals were killed on day 43. The treated patient rats showed a significant reduction in proteinuria, BUN, serum creatinine and serum cholesterol, as well as, administration of M‐2000 could significantly diminish the serum level of interleukin‐6 (IL‐6) in treated animals compared to non‐treated controls. Moreover, treatment with M‐2000 significantly reduced number of glomerular leukocytes, Hypercellularity and hydropic change in capillary network within the renal cortex and decreased tubular casts. These data suggest that M‐2000 therapy can ameliorate proteinuria, and suppress the progression of glomerular lesions in experimental model of nephrosis.
Immunopharmacology and Immunotoxicology
Immunology not elsewhere classified